The One-Time Shot That Edits Your DNA to Lower Cholesterol: VERVE-102, Explained

We've been tracking the cholesterol-drug frontier on this site — the oral PCSK9 pill enlicitide, which is secretly a macrocyclic peptide, and the spread of GLP-1 drugs into new indications. VERVE-102 is the far end of that same frontier, and it's a different category of thing entirely. It isn't a pill you take every day or a shot you take twice a year. It's a single intravenous infusion that goes into your liver and permanently rewrites one letter of your DNA, switching off a gene so your LDL cholesterol drops — and, in theory, stays down for the rest of your life.

In May 2026 the first peer-reviewed human data landed in the New England Journal of Medicine, and a few weeks earlier Eli Lilly had paid up to $1.3 billion to own it. Here's the honest breakdown — what it does, what the trials actually show, and the caveats that matter when you're talking about a treatment you can't undo.

What VERVE-102 actually is

VERVE-102 is an in vivo base-editing therapy. Let's unpack that.

The target is PCSK9 — the same protein the injectable PCSK9 inhibitors (Repatha, Praluent) and the oral one (enlicitide) all block. PCSK9 controls how many LDL receptors your liver keeps on its cells; those receptors are what pull "bad" LDL cholesterol out of your blood. Less PCSK9 means more receptors, which means more LDL cleared. People who are born with naturally low-functioning PCSK9 genes have very low LDL and strikingly low rates of heart disease, with no apparent downside. VERVE-102 is an attempt to give you that same genetics on purpose. [1][2]

The "base editing" part is the key distinction. VERVE-102 uses an adenine base editor — a tool derived from CRISPR — to change a single DNA base pair (an A-to-G swap) inside the PCSK9 gene, introducing a stop signal that permanently inactivates it. [1][3] This is not the CRISPR you may be picturing. Classic CRISPR-Cas9 cuts both strands of the DNA double helix and lets the cell stitch the break back together, which is error-prone. Base editing makes a precise single-letter chemical edit without cutting both strands — a meaningful safety argument, and the whole reason Verve bet on this approach. [3]

The delivery is the other clever piece. The editor (delivered as mRNA plus a guide RNA) is packaged inside a lipid nanoparticle decorated with GalNAc, a sugar tag that homes in on liver cells. [1][4] You get it as a single IV infusion of a few hours. Because the DNA edit is permanent in every cell it hits and in those cells' descendants, the pitch is one and done: one infusion, lifelong PCSK9 suppression, no daily pill, no recurring injections. [1]

The Heart-2 data: what the trial actually showed

The lead trial is Heart-2 (NCT06164730), a Phase 1b single-ascending-dose study. It enrolled 35 adults who either had heterozygous familial hypercholesterolemia (HeFH — the inherited high-cholesterol disorder) or premature coronary artery disease with high cholesterol that standard drugs weren't controlling. Patients were dosed across six weight-based cohorts, from 0.3 up to 1.0 mg/kg. [1][5]

The results were published in the New England Journal of Medicine on May 25, 2026 (and simultaneously presented at the European Atherosclerosis Society congress in Athens). [1][6] The headline numbers:

PCSK9 protein fell in a clean, dose-dependent way — from 51% at the lowest dose up to 88% at the top 1.0 mg/kg dose. [1]
LDL cholesterol dropped up to 62% at the top dose. [1]
The effect was durable up to 18 months in the patients followed longest — no sign of it wearing off, which is exactly what you'd want from a permanent edit. [1]

On safety — the thing everyone was watching, for reasons we'll get to — there were no dose-limiting toxicities, no treatment-related serious adverse events, and no withdrawals. Every patient got their full planned dose. The side effects were mild infusion-related reactions and fatigue, plus some transient liver-enzyme blips. Critically, there were no clinically significant liver-enzyme or platelet problems at any dose. [1][6]

One honest wrinkle worth flagging: the LDL-lowering wasn't a perfectly clean dose-ladder. The per-cohort LDL reductions ran roughly 9%, 44%, 45%, 33%, 51%, and 62% as the dose climbed — note the 0.7 mg/kg cohort came in lower than the 0.6 mg/kg one. [1] That's the kind of noise you get with a handful of patients per cohort, and the PCSK9 reduction (the direct molecular readout) was cleanly dose-dependent, so the wobble is almost certainly small-sample variability rather than a real signal. But it's the sort of detail the press releases smooth over, and worth knowing.

Why VERVE-102 exists: the VERVE-101 scare

You can't understand VERVE-102 without the drug that came before it. VERVE-101 was the first version — same PCSK9 target, same base editor, but an earlier lipid-nanoparticle design. In late 2023 it made history as the first in-vivo base-editing therapy ever tested in humans, knocking down PCSK9 by up to 84% and LDL by up to 55%. [7]

Then, in April 2024, the trial hit a wall. The sixth patient dosed at 0.45 mg/kg developed a Grade 3 transient liver-enzyme elevation and a Grade 3 drop in platelets within days of infusion — a serious, drug-related adverse event. Both fully resolved within days, with no bleeding or lasting harm, but Verve halted enrollment in that study. [8][9]

The company had already been developing VERVE-102 as a successor, and pivoted to it as the lead. VERVE-102 keeps the identical base editor and PCSK9 guide RNA but swaps in a redesigned lipid nanoparticle with the GalNAc liver-targeting tag, aimed at cleaner hepatocyte delivery and better tolerability. [9] The clean Heart-2 safety profile — no platelet or liver signal across all six cohorts — is the evidence that the redesign did its job. That's the whole arc: a scare, a re-engineered delivery vehicle, and a do-over that so far looks like it worked.

The $1.3 billion bet: Eli Lilly buys Verve

While the science was advancing, the ownership changed. On June 17, 2025, Eli Lilly announced it would acquire Verve Therapeutics. The deal: $10.50 a share in cash (about $1.0 billion) up front, plus a contingent value right worth up to $3.00 more — up to roughly $1.3 billion total. [10][11] The acquisition closed July 25, 2025. [12]

Two details tell the story. First, the price was a roughly 113% premium over Verve's recent trading average — but trade press still called it a "bargain," because Verve's stock had been beaten down after the VERVE-101 safety scare, so Lilly bought a recovering asset at a discount to its earlier valuation. [11][13] Second, that extra $3.00-per-share contingent payment is explicitly tied to the first patient being dosed with VERVE-102 for established cardiovascular disease (ASCVD) in a U.S. Phase 3 trial. [10] In other words, the deal terms themselves point at where this is ultimately headed: not just rare inherited disorders, but the enormous population of people with ordinary heart disease.

For Lilly — already the GLP-1 heavyweight with tirzepatide and retatrutide — VERVE-102 extends its cardiometabolic franchise into one-time genetic medicine. It's a bet that "cure it once" can sit alongside "manage it forever."

Where this fits: the whole spectrum of LDL-lowering

It helps to see VERVE-102 as one end of a spectrum that trades convenience and permanence against reversibility and maturity:

Approach	Examples	How often	LDL drop	Maturity
Oral pill	enlicitide (Merck), AZD0780 (AstraZeneca)	Daily	~50–65%	Phase 3 / Phase 2
Antibody injection	evolocumab (Repatha), alirocumab (Praluent)	Every 2–4 weeks	~60%	Approved, outcomes-proven
siRNA injection	inclisiran (Leqvio)	Twice a year	~36–55%	Approved
Gene edit	VERVE-102	Once, ever	up to ~62%	Phase 1/2

[14][15][16] Every step down that list removes an adherence burden — a daily pill becomes a twice-yearly shot becomes a single infusion. But the same arrow points at rising stakes: the pill you can stop tomorrow, the edit you cannot. VERVE-102 is the only one-and-done option, and also the least clinically mature and the only irreversible one.

It's worth naming that VERVE-102 isn't alone. CRISPR Therapeutics' CTX310 is editing a different liver gene (ANGPTL3) and reported its own Phase 1 data in late 2025 — LDL down up to 87%, triglycerides down up to 84% in the best responders. [17] A Chinese base editor, YolTech's YOLT-101, also targets PCSK9 and reported a 52% LDL drop in early 2026. [18] And Tune Therapeutics is pursuing an epigenetic approach that silences PCSK9 without changing the DNA sequence — pitched as potentially reversible, the direct counterpoint to permanent editing (though its cardiovascular work is still preclinical). [19] The field is real, and it's a race.

Verve's bigger plan: three genes, not one

VERVE-102 is the lead, but Lilly inherited a three-program pipeline, each switching off a different liver gene: [20]

VERVE-102 → PCSK9 → lowers LDL. (The one we've been discussing.)
VERVE-201 → ANGPTL3 → lowers both LDL and triglycerides, and works independently of the LDL receptor — which matters for patients whose LDL receptors barely function, like those with the severe homozygous form of familial hypercholesterolemia. It's in early-phase testing.
VERVE-301 → LPA → lowers lipoprotein(a), or Lp(a), a genetically determined risk factor that no pill can currently touch. It's the earliest-stage program, still preclinical.

The throughline is a vision of cardiovascular prevention done by editing the handful of liver genes that set your lifetime lipid levels — once.

The caveats that actually matter

This is where the honesty has to be front and center, because the marketing language ("functional cure," "one-and-done") runs ahead of the evidence in a few important ways.

It hasn't been shown to prevent a single heart attack. Every number above is LDL or PCSK9 — surrogate markers. No gene-editing cholesterol therapy has yet demonstrated that it reduces actual cardiovascular events. Lower LDL is tightly linked to fewer heart attacks as a class effect, so the expectation is reasonable, but the hard proof for this specific therapy is years away — Lilly only plans to start the Phase 2 study by the end of 2026, with outcomes data much later. [1] Don't let "cure" outrun "we measured a blood test."

You cannot undo it. This is the single biggest difference from every other drug on that spectrum. Stop a pill, and it clears your system; an antibody washes out in weeks. A DNA edit is permanent. If a long-term problem emerges years later, there's no off switch. That's not a reason to dismiss it — for the right high-risk patient it may be exactly the right trade — but it's the caveat that deserves the most weight.

"Permanent" is so far an extrapolation. The edit is permanent in each cell it changes, and liver cells turn over slowly, so durability should be long. But the demonstrated human durability is ~18 months. "Lifelong" is a reasonable expectation, not yet a proven fact. [1]

It is somatic, not heritable — get this right. This edits the DNA in your liver cells only. It is not germline editing; it does not change eggs or sperm and is not passed to your children. This is the most commonly muddled point in public discussion, and it's an important ethical distinction — somatic editing of one organ in a consenting adult is a completely different thing from editing embryos. [21]

Long tail, unknown price. The FDA requires up to 15 years of long-term safety follow-up for gene-editing therapies — a far longer leash than a conventional drug. [17] And no price has been set; one-time genetic medicines have historically carried very high price tags, and whether a one-time edit is cost-effective versus cheap generic statins for broad populations is a genuine open question. [22]

The takeaway

VERVE-102 is the most ambitious version of an idea this whole corner of medicine is circling: stop managing cardiovascular risk and start editing it out. The early human data are genuinely striking — an 88% drop in a disease-driving protein and a 62% LDL reduction from a single infusion, durable for a year and a half, with a safety profile that cleared the bar its predecessor tripped over. Lilly's $1.3 billion and the ASCVD-tied milestone show where the smart money thinks this goes.

But it is Phase 1/2, it has never been shown to prevent an actual cardiac event, and it is irreversible in a way nothing else in the cabinet is. The right frame isn't "the cure for heart disease is here." It's "the first credible human proof that you can edit a cholesterol gene safely is here, and the next decade will tell us whether it earns the word cure."

For anyone watching the legitimate, FDA-pipeline end of cardiometabolic medicine, that's the real story — the same one enlicitide tells from the pill side: the science is advancing fast, the right way, with the trials, the caveats, and the multi-year outcomes studies that the gray market never bothers with.

This article summarizes publicly reported clinical-trial data for educational purposes and is not affiliated with or endorsed by Verve Therapeutics or Eli Lilly. VERVE-102 is investigational and not FDA-approved. For research and educational purposes only. Not for human consumption. Not medical advice. Always consult a licensed physician.

Sources

Eli Lilly. "A Single Dose of Lilly's PCSK9 Base Editor VERVE-102 Reduced PCSK9 by up to 88% and LDL-C by up to 62% with Durable Effects." May 25, 2026. prnewswire.com
Science. "Base editing, a new form of gene therapy, sharply lowers 'bad' cholesterol." science.org
Frontiers in CRISPR / review of VERVE-101 base editing (mechanism, no double-strand break). Taylor & Francis. tandfonline.com
Verve Therapeutics. "VERVE-102 program page" (GalNAc-LNP dual-uptake delivery). vervetx.com
American Heart Association. "Heart-2 trial design abstract." Circulation. 2024;150(suppl_1):4139206. ahajournals.org
Verve Therapeutics / Lilly. VERVE-102 Heart-2 results, simultaneously published in the New England Journal of Medicine, doi:10.1056/NEJMoa2601283. nejm.org
Verve Therapeutics. "Verve Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing." November 12, 2023. globenewswire.com
HCPLive. "Verve Therapeutics Halts Enrollment of Heart-1 PCSK9 Gene Therapy Trial." hcplive.com
CGTLive. "Verve Moves On to Second-Gen Cardiovascular Therapy VERVE-102 After Adverse Events." cgtlive.com
Eli Lilly. "Lilly to Acquire Verve Therapeutics to Advance One-Time Treatments for People with High Cardiovascular Risk." June 17, 2025. investor.lilly.com
Pharmaceutical Technology. "Eli Lilly lands bargain deal to acquire Verve Therapeutics for $1.3bn." pharmaceutical-technology.com
Eli Lilly. "Lilly Completes Acquisition of Verve Therapeutics." July 25, 2025. investor.lilly.com
BioPharm International. "Lilly to Acquire Verve Therapeutics in Deal Targeting One-Time Gene-Editing Treatments for Cardiovascular Disease." biopharminternational.com
Merck. "Enlicitide Decanoate Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial." merck.com
AstraZeneca. "AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL-C reduction in PURSUIT Phase IIb trial." March 31, 2025. astrazeneca.com
Inclisiran bench-to-bedside review. Journal of the American Heart Association. ahajournals.org
CRISPR Therapeutics. "Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing." November 8, 2025 (+ AHA newsroom on 15-year FDA follow-up). globenewswire.com
Inside Precision Medicine. "HeFH Base Editor (YolTech YOLT-101) Shows Promise in Chinese Clinical Trial." insideprecisionmedicine.com
Tune Therapeutics. Durable epigenetic PCSK9 repression in non-human primates. Nature Medicine. nature.com
Verve Therapeutics. "Verve Announces Pipeline Progress and Anticipated 2025 Milestones" (VERVE-102 / -201 / -301). January 13, 2025. globenewswire.com
The Conversation. "Somatic genome editing therapies are becoming a reality — but debate over ethics, equitable access and governance continues." theconversation.com
European Heart Journal. "Gene therapy and genome editing for lipoprotein disorders" (off-target, regulatory, cost considerations). academic.oup.com